ARTICLE | Company News
Micromet, Tracon deal
March 19, 2007 7:00 AM UTC
MITI granted Tracon exclusive, worldwide rights to develop and commercialize D93 to treat cancer. In 2H07, Tracon plans to begin a Phase I trial of the recombinant humanized IgG1 MAb that inhibits an...